Q2 2025 Boston Scientific Corp Earnings Call Transcript
Key Points
- Boston Scientific Corp (BSX) reported a strong second quarter with operational sales growth of 22% and organic sales growth of 17%, exceeding their guidance range.
- The Cardiovascular segment led the growth, with notable performances from products like FARAPULSE, WATCHMAN, and Complex PCI.
- The company raised its full-year guidance for organic growth from 12%-14% to 14%-15%, reflecting strong momentum across global businesses.
- Adjusted EPS for the second quarter was $0.75, a 23% increase, surpassing the high end of the guidance range.
- The company successfully closed acquisitions, such as Sona and Entera Oncology, which are expected to complement existing business segments and drive future growth.
- The discontinuation of the ACURATE valve resulted in significant charges, impacting gross margins and leading to inventory write-downs.
- Despite strong overall performance, the adjusted gross margin declined by 100 basis points due to inventory charges related to the ACURATE valve discontinuation.
- The Urology segment faced challenges with supply chain constraints and low-cost competition, impacting growth.
- The Peripheral Interventions segment experienced only low single-digit growth in certain areas, such as arterial and drug-eluting products.
- The company anticipates a $100 million headwind from tariffs for the full year, impacting financial performance.
Good morning, and welcome to the Boston Scientific second quarter 2025 earnings call. (Operator Instructions) Please note this event is being recorded.
I would now like to turn the conference over to Lauren Tengler, Vice President, Investor Relations. Please go ahead.
Thank you, Drew, and thanks to everyone for joining us today. With me on today's call are Mike Mahoney, Chairman and Chief Executive Officer; and John Monson, Executive Vice President and Chief Financial Officer. During the Q&A session, Mike and John will be joined by our Chief Medical Officer, Dr. Ken Stein. We issued a press release earlier this morning announcing our Q2 results, which included reconciliations of the non-GAAP measures.
The release as well as reconciliations of the non-GAAP measures used in today's call can be found on the Investor Relations section of our website. Please note that on the call, operational revenue excludes the impact of foreign currency fluctuations, and organic
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
